Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short term Debt (2021 - 2025)

Indivior Pharmaceuticals has reported Short term Debt over the past 5 years, most recently at $29.0 million for Q4 2025.

  • Quarterly results put Short term Debt at $29.0 million for Q4 2025, up 61.11% from a year ago — trailing twelve months through Dec 2025 was $29.0 million (up 61.11% YoY), and the annual figure for FY2025 was $29.0 million, up 61.11%.
  • Short term Debt for Q4 2025 was $29.0 million at Indivior Pharmaceuticals, up from $18.0 million in the prior quarter.
  • Over the last five years, Short term Debt for INDV hit a ceiling of $29.0 million in Q4 2025 and a floor of $3.0 million in Q4 2021.
  • Median Short term Debt over the past 5 years was $18.0 million (2024), compared with a mean of $13.8 million.
  • Biggest five-year swings in Short term Debt: changed 0.0% in 2022 and later surged 500.0% in 2024.
  • Indivior Pharmaceuticals' Short term Debt stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then surged by 500.0% to $18.0 million in 2024, then skyrocketed by 61.11% to $29.0 million in 2025.
  • The last three reported values for Short term Debt were $29.0 million (Q4 2025), $18.0 million (Q3 2025), and $18.0 million (Q2 2025) per Business Quant data.